Yahoo
NasdaqGS - Delayed Quote USD

4D Molecular Therapeutics, Inc. (FDMT)

10.49 +0.43 (+4.27%)
At close: April 17 at 4:00:01 PM EDT
10.57 +0.08 (+0.76%)
After hours: April 17 at 7:19:00 PM EDT
Trade FDMT on Coinbase
Chart Range Bar
Loading chart for FDMT
  • Previous Close 10.06
  • Open 10.48
  • Bid 10.47 x 300
  • Ask 10.53 x 200
  • Day's Range 10.21 - 10.74
  • 52 Week Range 2.96 - 12.34
  • Volume 894,935
  • Avg. Volume 765,588
  • Market Cap (intraday) 535.53M
  • Beta (5Y Monthly) 2.93
  • PE Ratio (TTM) --
  • EPS (TTM) -2.42
  • Earnings Date (est.) May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 28.78

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

www.4dmoleculartherapeutics.com

196

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: FDMT

Trailing total returns as of 4/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FDMT
39.87%
S&P 500 (^GSPC)
4.10%

1-Year Return

FDMT
242.81%
S&P 500 (^GSPC)
34.89%

3-Year Return

FDMT
37.07%
S&P 500 (^GSPC)
71.66%

5-Year Return

FDMT
68.40%
S&P 500 (^GSPC)
70.26%

Earnings Trends: FDMT

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 85.09M
Earnings 19.4M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-50M
0
50M

Analyst Insights: FDMT

View More

Analyst Price Targets

17.00
28.78 Average
10.49 Current
38.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/20/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 36 -> 36

Statistics: FDMT

View More

Valuation Measures

Annual
As of 4/16/2026
  • Market Cap

    514.09M

  • Enterprise Value

    132.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.85

  • Price/Book (mrq)

    1.02

  • Enterprise Value/Revenue

    1.56

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -164.43%

  • Return on Assets (ttm)

    -17.34%

  • Return on Equity (ttm)

    -27.57%

  • Revenue (ttm)

    85.21M

  • Net Income Avi to Common (ttm)

    -140.11M

  • Diluted EPS (ttm)

    -2.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    402.66M

  • Total Debt/Equity (mrq)

    4.24%

  • Levered Free Cash Flow (ttm)

    -54.15M

Compare To: FDMT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: FDMT

Fair Value

10.49 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: